Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade Glioma

Next Previous
Trial Profile

A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade Glioma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disufenton (Primary)
  • Indications Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oblato

Most Recent Events

  • 05 Oct 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study not proceeding and sites never opened.
  • 26 Sep 2021 Planned End Date changed from 1 Apr 2024 to 1 Aug 2025.
  • 26 Sep 2021 Planned primary completion date changed from 1 Feb 2024 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top